Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)

  Print   

Wednesday 27 April, 2022

BioPharma Credit PLC

Dividend Declaration

RNS Number : 5959J
BioPharma Credit PLC
27 April 2022
 

BIOPHARMA CREDIT PLC 

("BIOPHARMA CREDIT" OR THE "COMPANY") 

DIVIDEND DECLARATION

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 31 March 2022 of $0.0175 per ordinary share, payable on 31 May 2022 to ordinary shareholders on the register as at 6 May 2022. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.

The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.

The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 6 May 2022 (the "Election Date").

Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at  www.bpcruk.com/investor-materials . CREST shareholders must elect via CREST. Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at  www.bpcruk.com/investor-materials . CREST shareholders must elect via CREST.

LEI: 213800AV55PYXAS7SY24

-Ends-

Link Company Matters Limited

Company Secretary

 

27 April 2022

 

Enquiries:

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

[email protected]

 

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVIRMFTMTBTBTT

a d v e r t i s e m e n t